Abstract
There is an urgent need for new antimycobacterial drugs, and in particular for novel agents that will shorten the duration of tuberculosis chemotherapy, or overcome drug-resistant strains of the causative organism, Mycobacterium tuberculosis. Our knowledge of the tubercle bacillus and its complex interaction with the human host has improved dramatically in recent years, particularly with the determination of its complete genome sequence. New genome-scale tools are being applied to aid in drug target identification, alongside traditional approaches aimed at understanding the basic biology of M. tuberculosis. Many potential drug targets have been identified, but very few have been validated by showing that they are essential for growth or survival of the bacterium. In this review, the landscape of potential drug targets is surveyed.
Keywords: tuberculosis, mycobacterium tuberculosis, genomic sequencing, microarray technology, mycolic acid, regulatory proteins, smegmatis
Current Pharmaceutical Design
Title: Identification and Validation of Novel Drug Targets in Tuberculosis
Volume: 10 Issue: 26
Author(s): K. Duncan
Affiliation:
Keywords: tuberculosis, mycobacterium tuberculosis, genomic sequencing, microarray technology, mycolic acid, regulatory proteins, smegmatis
Abstract: There is an urgent need for new antimycobacterial drugs, and in particular for novel agents that will shorten the duration of tuberculosis chemotherapy, or overcome drug-resistant strains of the causative organism, Mycobacterium tuberculosis. Our knowledge of the tubercle bacillus and its complex interaction with the human host has improved dramatically in recent years, particularly with the determination of its complete genome sequence. New genome-scale tools are being applied to aid in drug target identification, alongside traditional approaches aimed at understanding the basic biology of M. tuberculosis. Many potential drug targets have been identified, but very few have been validated by showing that they are essential for growth or survival of the bacterium. In this review, the landscape of potential drug targets is surveyed.
Export Options
About this article
Cite this article as:
Duncan K., Identification and Validation of Novel Drug Targets in Tuberculosis, Current Pharmaceutical Design 2004; 10 (26) . https://dx.doi.org/10.2174/1381612043383223
DOI https://dx.doi.org/10.2174/1381612043383223 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells
Current Medicinal Chemistry Imidazole and 1,2,4-Triazole-based Derivatives Gifted with Antitubercular Activity: Cytotoxicity and Computational Assessment
Current Topics in Medicinal Chemistry The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Flexibility in the Molecular Design of Acetylcholinesterase Reactivators: Probing Representative Conformations by Chemometric Techniques and Docking/QM Calculations
Letters in Drug Design & Discovery Bioactive Peptides from Marine Sources as Potential Anti-Inflammatory Therapeutics
Current Protein & Peptide Science Treatment of Tuberculosis: Use of Active Pharmaceuticals
Recent Patents on Anti-Infective Drug Discovery G-quadruplex DNA Aptamers and their Ligands: Structure, Function and Application
Current Pharmaceutical Design Editorial (Thematic Issue: New Developments in the Search for Agents to Treat Tuberculosis)
Current Topics in Medicinal Chemistry Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Multiple Myeloma or Brucellosis: A Case Report
Infectious Disorders - Drug Targets Synthesis and Biological Activity of Chiral Dihydropyrazole: Potential Lead for Drug Design
Mini-Reviews in Medicinal Chemistry Iodocyclization, Followed by Palladium-Catalyzed Coupling: A Versatile Strategy for Heterocyclic Library Construction
Combinatorial Chemistry & High Throughput Screening HIV-1 Vpr: A Closer Look at the Multifunctional Protein from the Structural Perspective
Current HIV Research Prospects of Bacteriotherapy with Nanotechnology in Nanoparticledrug Conjugation Approach for Cancer Therapy
Current Medicinal Chemistry Antimicrobial Peptides with pH-Dependent Activity and Alkaline Optima: Their Origins, Mechanisms of Action and Potential Applications
Current Protein & Peptide Science Diagnosis and Treatment of Drug-Resistant Tuberculosis: State of the Art
Current Respiratory Medicine Reviews Molecular Pathways of Interferon-Stimulated Gene 15: Implications in Cancer
Current Protein & Peptide Science Trends in Enzyme Inhibition and Activation in Drug Design - Part II
Current Topics in Medicinal Chemistry Alternative Nucleophilic Residues in Intein Catalysis of Protein Splicing
Protein & Peptide Letters Resveratrol Targets in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets